Cargando…

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway

A glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (LR) had been experimentally and clinically shown to ameliorate nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the beneficial effect of LR on NAFLD in vivo and in vitro and its underlying molecular mechanism. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Peng, Xu, Xi, Zhang, Jing, Xia, Xuan, Xu, Fen, Weng, Jianping, Lai, Xiaoyang, Shen, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545813/ https://www.ncbi.nlm.nih.gov/pubmed/31236111 http://dx.doi.org/10.1155/2019/1567095

Ejemplares similares

SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway
por: Kim, Da Eun, et al.
Publicado: (2020)

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Yan, Jinhua, et al.
Publicado: (2019)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
por: Zhang, Ningjing, et al.
Publicado: (2020)

Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway
por: WANG, YAN-GUI, et al.
Publicado: (2015)

Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway
por: Ye, Jiena, et al.
Publicado: (2022)

A Novel Identified Peptide Hormone “Metabolitin” Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway
por: Xu, Peng, et al.
Publicado: (2021)

MicroRNA regulation of AMPK in nonalcoholic fatty liver disease
por: Sun, Hao, et al.
Publicado: (2023)

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
por: Guo, Tingli, et al.
Publicado: (2023)

Citrus maxima and tea regulate AMPK signaling pathway to retard the progress of nonalcoholic fatty liver disease
por: Wen, Shuai, et al.
Publicado: (2022)

Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway
por: Song, Shuang, et al.
Publicado: (2022)

Hepatic leukocyte immunoglobulin‐like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1‐TRAF6 pathway
por: Lu, Yao, et al.
Publicado: (2018)

Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling
por: Zhang, Bo, et al.
Publicado: (2023)

Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
por: Yang, Mengying, et al.
Publicado: (2020)

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus
por: Kohut, Taisa, et al.
Publicado: (2021)

Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways
por: Li, Chun-Xiao, et al.
Publicado: (2019)

Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis–Related Cirrhosis With Liraglutide
por: Yuen, Christina, et al.
Publicado: (2023)

Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway
por: Zheng, Tao, et al.
Publicado: (2018)

A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
por: Yan, Chenghui, et al.
Publicado: (2021)

Liraglutide attenuates the osteoblastic differentiation of MC3T3-E1 cells by modulating AMPK/mTOR signaling
por: Hu, Xiong-Ke, et al.
Publicado: (2016)

A20 Attenuates FFAs-induced Lipid Accumulation in Nonalcoholic Steatohepatitis
por: Ai, Luoyan, et al.
Publicado: (2015)

Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy
por: Jang, Hyun-Jun, et al.
Publicado: (2023)

Inhibition of TREM‐1 attenuates inflammation and lipid accumulation in diet‐induced nonalcoholic fatty liver disease
por: Rao, Shenzong, et al.
Publicado: (2019)

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
por: Pei, Ke, et al.
Publicado: (2020)

Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Song, Tiantian, et al.
Publicado: (2021)

Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
por: Zhao, Yan, et al.
Publicado: (2023)

Icaritin Attenuates Lipid Accumulation by Increasing Energy Expenditure and Autophagy Regulated by Phosphorylating AMPK
por: Wu, Yue, et al.
Publicado: (2021)

LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
por: Chen, Xue-Yang, et al.
Publicado: (2019)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang, Pijian, et al.
Publicado: (2019)

Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
por: Li, Xiao-Yun, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
por: Fon Tacer, Klementina, et al.
Publicado: (2011)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
por: Bhat, Neha, et al.
Publicado: (2023)

Increased RTN3 phenocopies nonalcoholic fatty liver disease by inhibiting the AMPK–IDH2 pathway
por: Huang, Hao, et al.
Publicado: (2023)

Nobiletin Intake Attenuates Hepatic Lipid Profiling and Oxidative Stress in HFD-Induced Nonalcoholic-Fatty-Liver-Disease Mice
por: Ke, Zunli, et al.
Publicado: (2023)

Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway
por: Wang, Yan-Gui, et al.
Publicado: (2015)

Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway
por: Zhang, Jing, et al.
Publicado: (2020)

Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206
por: Chen, Xi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0ajl83t4dm3vf2s8koh5n5dq7